Mike Quigley, executive director of Immuno-Oncology and Bo Barnhart, senior director of Immuno-Oncology at Bristol-Myers Squibb Redwood City (from left to right)

Mike Quigley, executive director of Immuno-Oncology and Bo Barnhart, senior director of Immuno-Oncology at Bristol-Myers Squibb Redwood City, Calif. (from left to right)

Scientists on the Move

May 04, 2018

A

t Bristol-Myers Squibb, our R&D team follows the science – sometimes literally. As we’ve expanded our R&D footprint across the globe, several colleagues have seized the opportunity to explore new areas of science in new geographies, from new states to new continents.

Mike Quigley, executive director of Immuno-Oncology (I-O),  is getting ready to make a cross-country move from Lawrenceville, N.J. to Redwood City – a move he’s made before. Quigley’s career with Bristol-Myers Squibb started in Redwood City, where he worked for three years before heading east to be closer to family. Now, Quigley is heading back to Redwood City to lead a translational team focused on understanding mechanisms of I-O resistance. His team, which comprises other East Coast transplants along with new hires from the Bay Area, will be working out of new state-of-the-art labs opened in April 2018.

“Embedding our resistance team in Redwood City, which is an engine of I-O discovery, will facilitate fast, real-time decisions that can inform the science in earlier stages,” Quigley said.

Bo Barnhart, senior director of Immuno-Oncology, has also made a cross-country move to join the I-O team in Redwood City. Barnhart joined Bristol-Myers Squibb’s oncology discovery team in Lawrenceville, after completing his post-doctoral studies at the University of Pennsylvania. After six years in Lawrenceville, he was excited by the opportunity to join a team led by Nils Lonberg and Alan Korman, pioneers in the field of I-O discovery research, and the vibrant Bay Area life science community. Ultimately, he found that while he might be 3,000 miles away from his former lab in New Jersey, the spirit of discovery and exploration spans across all R&D sites.

“One of the real strengths of Bristol-Myers Squibb is that researchers are given the freedom and support to follow a mechanism to understand the biology and how it works before we then try to apply it to drug discovery. That’s true no matter where you are in the company,” Barnhart said

Mohan Pandey, head of strategy and operations for Innovative Medicines, couldn’t agree more that the Bristol-Myers Squibb culture of discovery and innovation transcends geographic borders. Prior to moving to Lawrenceville in 2017, Pandey was the executive director of Bristol-Myers Squibb India and Head of BBRC (Biocon BMS R&D Center), an integrated R&D center operationalized in partnership with Syngene International.

“The operational model for BBRC is really visionary and it’s part of why I joined the company in 2007,” said Pandey. “After running that site for several years, I was excited by the opportunity to join the Innovative Medicines team in Lawrenceville, which also embraces an inventive and entrepreneurial model.”

It was a big move, but Bristol-Myers Squibb made the transition from India to Lawrenceville as seamless as possible. The one thing Pandey wasn’t prepared for was the historic snowfall amounts in New Jersey this year.

“It was quite an introduction to winter,” Pandey said. “But my kids really enjoyed their first experience with snow.”

Even has he adjusts to life in the U.S. – and driving on the right side of the road – Pandey is still open to the idea of moving again with Bristol-Myers Squibb in the future. “We are a global company, so who knows where the next opportunity may be.”

Related Content

Mike Quigley, Executive Director of Immuno-Oncology

Mike Quigley, Ph.D.

 Executive Director of Immuno-Oncology

Bo Barnhart, Senior Director of Immuno-Oncology

Bryan (Bo) Barnhart, Ph.D.

Senior Director, Immuno-Oncology, Discovery